etoposide phosphate has been researched along with etoposide in 95 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.05) | 18.7374 |
| 1990's | 39 (41.05) | 18.2507 |
| 2000's | 23 (24.21) | 29.6817 |
| 2010's | 22 (23.16) | 24.3611 |
| 2020's | 10 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Boven, E; De Vries, R; Haisma, HJ; Pinedo, HM; van Muijen, M | 1 |
| Doyle, TW; Vyas, DM | 1 |
| Senter, PD | 1 |
| Basler, GA; Casazza, AM; Crosswell, AR; Rose, WC; Saulnier, M; Trail, PA | 1 |
| Ashe, SA; Hellström, I; Hellström, KE; Hirschberg, DL; Schreiber, GJ; Senter, PD | 1 |
| Greco, FA; Hainsworth, JD | 2 |
| Bukowski, R; Fields, SZ; Gandara, D; Goss, G; Igwemezie, LN; Kaul, S; Kosty, M; Levithan, N; O'Dwyer, P; Stewart, DJ | 1 |
| Barbhaiya, RH; Igwemezie, LN; Kaul, S | 1 |
| Belani, CP; Greco, FA; Hainsworth, JD; Levitan, N; Randolph, J; Schacter, LP; Seyedsadr, MS; Wampler, GL | 1 |
| Barbhaiya, RH; Garrow, C; Greco, A; Hainsworth, JD; Igwenezue, KB; Kaul, S; Miller, AA; Schacter, LP; Srinivas, NR; Thompson, DS | 1 |
| Cavalli, F; Cerny, T; De Fusco, M; De Jong, J; Gentili, D; McDaniel, C; Pagani, O; Prins, C; Sessa, C; Zucchetti, M | 1 |
| Albert, E; Igwemezie, LN; Morgenthien, E; Randolph, J; Santabárbara, P; Schacter, LP; Seyedsadr, M | 1 |
| Allen, SL; Behr, J; Budman, DR; Hock, K; Igwemezie, LN; Kaul, S; Kolitz, J; Lichtman, S; Schulman, P; Vinciguerra, V | 1 |
| Balmanno, K; Chapman, F; Charlton, CJ; Gumbrell, L; Igwemezie, LN; Lind, MJ; Millward, MJ; Mummaneni, V; Newell, DR; Proctor, M | 1 |
| Baer, J; Budman, DR; Fields, SZ; Hock, K; Ingram, R; Kreis, W; Schacter, LP; Vinciguerra, V | 1 |
| Abigerges, D; Armand, JP; Bonnay, M; Chabot, GG; de Forni, M; Igwemezie, L; Kaul, S; Ropers, J; Schacter, L; Terret, C; Winograd, B | 1 |
| Alberts, DS; Barbhaiya, RH; Brooks, DJ; Igwemzie, LM; Kaul, S; McKinney, LM; Randolph, J; Schacter, L; Srinivas, NR; Thomas, T | 1 |
| Behr, J; Budman, DR; Cherny, RC; Fields, SZ; Ingram, R; Kreis, W; Schacter, LP; Schulman, P; Snow, C; Wright, J; Young, RR | 1 |
| Beijnen, JH; Koks, CH; Witterland, AH | 1 |
| Schacter, L | 1 |
| Budman, DR | 1 |
| Barbhaiya, RH; Igwemezie, LN; Kaul, S; Srinivas, NR | 1 |
| Barbhaiya, RH; Igwemezie, LN; Kaul, S; Mummaneni, V; Srinivas, NR | 1 |
| Alberts, DS; Brooks, DJ | 1 |
| Abrahamsen, D; Boddy, A; Brampton, M; Calvert, AH; Lind, M; Newell, D; Porter, D; Robson, L; Thomas, H; Winograd, B | 1 |
| Dezii, CM; Doyle, JJ; Sadana, A | 1 |
| Barbhaiya, RH; Calvert, AH; Igwemezie, LN; Kaul, S; Mummaneni, V; Newell, DR; Porter, D; Thomas, H; Winograd, B | 1 |
| Creaven, PJ; Gunton, KE; Meropol, NJ; Noel, D; Pendyala, L; Schacter, LP; Soni, N | 1 |
| Finch, RA; Flavell, RA; Lorico, A; Rappa, G; Sartorelli, AC; Yang, D | 1 |
| de Jong, RS; de Vries, EG; Mulder, NH; Slijfer, EA; Uges, DR | 1 |
| Greco, FA; Hainsworth, JD; Utley, SM | 1 |
| Beijnen, JH; Borst, P; Scheffer, GL; Scheper, RJ; van der Valk, M; van der Valk, P; Wijnholds, J | 1 |
| Barbhaiya, RH; Fields, SZ; Himpler, BS; Igwemezie, LN; Kaul, S; Litam, PP; McAleer, C; Schacter, LP; Schilder, RJ; Wright, J | 1 |
| Higgins, A; Joel, S; O'Byrne, K; Papamichael, D; Penson, R; Robertshaw, H; Rudd, R; Slevin, M; Talbot, D | 1 |
| Mrestani, Y; Neubert, R | 1 |
| Lauer, AK; Neuwelt, EA; Shults, WT; Wilson, MW; Wobig, JL | 1 |
| Bernstein, BJ; Troner, MB | 1 |
| Coroneo, M; Crouch, R; Graham, G; Morlet, N; Naidoo, D; Salonikas, C; Stayt, J | 1 |
| Benz, MS; Kramer, D; Murray, TG; Scott, IU; Toledano, S | 1 |
| Fortin, D; McCormick, CI; Neuwelt, EA; Nixon, R; Remsen, LG | 1 |
| Alscher, A; Casper, J; Decker, S; Freund, M; Junghanss, C; Kleine, HD; Knopp, A; Köhne, CH; Leithäuser, M; Wilhelm, S | 1 |
| Andresen, P; Blaschke, G; Hempel, G; Schierenberg, MO; Schulz, H; Soetebeer, UB | 1 |
| Breton, JL; Coëtmeur, D; Daniel, C; Debieuvre, D; Jacoulet, P; Kessler, R; Lemarié, E; Milleron, B; Moreau, L; Paillot, N; Quoix, E | 1 |
| Grimm, J; Jaehde, U; Kingreen, D; Kloft, C; Reif, S; Schunack, W; Siegert, W | 1 |
| De Boer, R; Desai, J; Prasad, P; Siderov, J | 1 |
| Demperio, VL | 1 |
| Briggs, A; Chow, HH; Dorr, RT; Kintzel, P; List, A; Meyers, R | 1 |
| Doolittle, ND; Kraemer, DF; Lacy, C; Neutwelt, EA; Siegal, T; Tyson, RM | 1 |
| Cho, YJ; Jeon, GA; Kim, KY; Myeong, JN; Ryu, PD | 1 |
| Braybrooke, JP; Davis, T; Harris, AL; Joel, S; Levitt, NC; Madhusudan, S; Talbot, DC; Turley, H; Wilner, S | 1 |
| Astruc, J; Barret, JM; Chansard, N; Créancier, L; Duchier, C; Hill, BT; Kruczynski, A; Menon, Y; Van Hille, B | 1 |
| Faubel, W; Heissler, S; Pütz, M; Pyell, U; Ragozina, NY | 1 |
| Castro, MA; del Corral, JM; García, PA; Gómez-Zurita, MA; Gordaliza, M | 1 |
| Aubin, F; Burgot, G; Gandemer, V; Le Gall, E; Marigny, K | 1 |
| Bain, LJ; Belinsky, MG; Chen, ZS; Dawson, PA; Grinberg, A; Klein-Szanto, A; Kruh, GD; Lerro, A; Ling, V; Shchaveleva, I; Wang, R; Westphal, H | 1 |
| Braybrooke, JP; Davies, SL; Echeta, C; Flanagan, E; Ganesan, TS; Hickson, ID; Joel, S; Levitt, NC; Madhusudan, S; Propper, DJ; Te Poele, R | 1 |
| Burris, HA; Corso, SW; Erland, JB; Greco, FA; Hainsworth, JD; Joseph, G; Morrissey, LH; Spigel, DR; Spremulli, E; Thompson, DS | 1 |
| Beneytout, JL; Leger, DY; Liagre, B | 1 |
| Collier, K; How, K; Savage, P; Schink, C; Seckl, M; Young, AM | 1 |
| Bell, SD; Bourekas, EC; Macnealy, MW; McGregor, JM; Newton, HB; Ray Chaudhury, A; Slone, HW | 1 |
| Lv, M; Tian, X; Xu, H | 1 |
| Bonnabry, P; Fleury-Souverain, S; Geiser, L; Hochstrasser, D; Nussbaumer, S; Sadeghipour, F; Veuthey, JL | 1 |
| Lv, M; Xu, H | 1 |
| Gaynon, P; Lindsay, H | 1 |
| Bonnabry, P; Fleury-Souverain, S; Mattiuzzo, M; Nussbaumer, S | 1 |
| Kokache, A; Mahmoud, S; Sambasivan, K; Savage, P; Seckl, M | 1 |
| Calabrese, D; Dietsche, T; Dill, MT; Duong, FH; Heim, MH; Ketterer, S; Makowska, Z; Matter, MS; Terracciano, L | 1 |
| Bharatam, PV; Choudhuri, M; Das, D; Guchhait, SK; Jain, V; Kandekar, S; Kashyap, M; Kundu, CN; Mohapatra, P; Preet, R; Renu Prasad, MU; Satapathy, SR; Siddharth, S | 1 |
| Madsen, HO; Minculescu, L; Sengeløv, H | 1 |
| Bourneau-Martin, D; Drablier, G; Lagarce, L; Lainé-Cessac, P; Le Louet, H; Leguay, Z; Pellier, I | 1 |
| Huang, L; Satterlee, A; Srinivas, R; Wang, Y; Zhang, Y | 1 |
| Joshi, A; Patel, H; Stagni, G | 2 |
| Cirillo, M; O'Sullivan, M; Polistena, P; Purtill, D; Tran, Q | 1 |
| Fu, L; Hu, D; Li, Y; Su, L; Yang, F; Zhang, M | 1 |
| Elner, VM; Harbour, JW; Mohney, BG; Musch, DC; Smith, AB; Smith, BD; Smith, SJ | 1 |
| Bouchaert, E; Boyé, P; Gomes, B; Hordeaux, J; Marescaux, L; Serres, F; Tierny, D | 1 |
| Chastagner, P; Clément, L; Clerc-Urmès, I; Cordero, C; Loboda, C; Pochon, C | 1 |
| Ding, Z; Hai, Z; Kiran, S; Liang, G; Liu, Y; Wang, L; Zhang, H | 1 |
| Barnoud, D; Barthélémy, C; Béné, J; Bruno, B; Décaudin, B; Gautier, S; Lahoche, A; Odou, P; Petitpain, N; Pinçon, C; Simon, N; Vasseur, M | 1 |
| Barnoud, D; Béné, J; Bruno, B; Odou, P; Simon, N; Vasseur, M | 1 |
| Beachman, J; Behera, S; Berkahn, L; Costello, I; Gu, Y; Naidoo, N; Raina, T; Svirskis, D; Zhou, Y | 1 |
| Azmy, V; Brooks, JP; Hsu, FI; Luon, D; Price, C; Prozora, SD; Thompson, A | 1 |
| Aouati, H; Babiard, M; Bellanger, A; Do, B; Hassani, L; Rietveld, IB; Sadou Yayé, H; Secrétan, PH; Tilleul, P; Yagoubi, N | 1 |
| Aye, J; Beierle, EA; Clay, MR; Coleman, A; Hoppmann, A; Mroczek-Musulman, E; Ranganathan, S; Tynes, C; Whelan, KF; Williams, AP; Williams, GR | 1 |
| Boyé, P; Floch, F; Fournel-Fleury, C; Serres, F; Tierny, D | 1 |
| Al-Rohil, RN; Bentley, RC; Cardona, DM; Feng, X; Jour, G; Shen, G; Underwood, CIM | 1 |
| Barboro, P; Boccardo, F; Capaia, M; Cattrini, C | 1 |
| Bas, EG; Celen, S; Daloglu, H; Hazar, V; Kabakci, C; Karasu, GT; Pashayev, D; Pehlivan, B; Uygun, V; Yalcin, K; Yesilipek, A; Zhumatayev, S | 1 |
| Gilbar, PJ; Grewal, GD; Pringle, NR | 1 |
| Béné, MC; Chevallier, P; Eveillard, M; Garnier, A; Guillaume, T; Jullien, M; Le Bourgeois, A; Peterlin, P; Seguin, A | 1 |
| Dowling, M; Grigg, A; Janson, B; Khot, A; Siderov, J; Stewart, T; Xie, J | 1 |
9 review(s) available for etoposide phosphate and etoposide
| Article | Year |
|---|---|
Second generation analogs of etoposide and mitomycin C.
Topics: Animals; Antineoplastic Agents; Dogs; Drug Screening Assays, Antitumor; Etoposide; Humans; Mice; Mitomycin; Mitomycins; Organophosphorus Compounds | 1990 |
Etoposide phosphate, the water soluble prodrug of etoposide.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase I as Topic; Etoposide; Humans; Organophosphorus Compounds; Prodrugs; Solubility; Water | 1996 |
Etoposide phosphate: what, why, where, and how?
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Clinical Trials as Topic; Etoposide; Humans; Lung Neoplasms; Organophosphorus Compounds; Podophyllotoxin | 1996 |
Early studies of etoposide phosphate, a water-soluble prodrug.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Etoposide; Humans; Organophosphorus Compounds; Prodrugs | 1996 |
Sarah Cannon Cancer Center Consensus Conference on Novel Developments with Podophyllotoxin Therapy.
Topics: Antineoplastic Agents, Phytogenic; Etoposide; Humans; Organophosphorus Compounds; Podophyllotoxin; Prodrugs | 1996 |
Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives.
Topics: Cytotoxins; Etoposide; Lignans; Organophosphorus Compounds; Plants, Toxic; Podophyllotoxin; Teniposide; Tumor Cells, Cultured | 2004 |
A review on hemisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: 2003-2007.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Etoposide; Humans; Inhibitory Concentration 50; Organophosphorus Compounds; Podophyllotoxin; Structure-Activity Relationship; Teniposide | 2009 |
Recent advances in semisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: an update (2008-2010).
Topics: Antineoplastic Agents, Phytogenic; Cell Survival; Drug Screening Assays, Antitumor; Etoposide; Humans; Organophosphorus Compounds; Podophyllotoxin; Structure-Activity Relationship; Teniposide | 2011 |
Immediate severe hypersensitivity reaction to etoposide phosphate: Case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Drug Hypersensitivity; Etoposide; Humans; Male; Organophosphorus Compounds; Young Adult | 2022 |
27 trial(s) available for etoposide phosphate and etoposide
| Article | Year |
|---|---|
Etoposide phosphate or etoposide with cisplatin in the treatment of small cell lung cancer: randomized phase II trial.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organophosphorus Compounds; Treatment Outcome | 1995 |
Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Biological Availability; Chromatography, High Pressure Liquid; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Organophosphorus Compounds; Therapeutic Equivalency | 1995 |
Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organophosphorus Compounds; Survival Analysis | 1995 |
A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days.
Topics: Adult; Aged; Antineoplastic Agents; Chromatography, High Pressure Liquid; Cohort Studies; Dose-Response Relationship, Drug; Etoposide; Female; Half-Life; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Organophosphorus Compounds | 1995 |
Phase I clinical and pharmacokinetic study of oral etoposide phosphate.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Biological Availability; Drug Administration Schedule; Etoposide; Humans; Injections, Intravenous; Lymphoma; Middle Aged; Models, Biological; Neoplasms; Neutropenia; Organophosphorus Compounds; Prodrugs | 1995 |
Clinical and pharmacokinetic overview of parenteral etoposide phosphate.
Topics: Animals; Blood Pressure; Drug Administration Schedule; Etoposide; Humans; Infusions, Intravenous; Leukocyte Count; Neoplasms; Organophosphorus Compounds | 1994 |
Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors.
Topics: Adult; Aged; Alopecia; Chromatography, High Pressure Liquid; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Organophosphorus Compounds; Prodrugs; Regression Analysis; Solubility; Vomiting | 1994 |
Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481).
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Organophosphorus Compounds; Ovarian Neoplasms; Prodrugs | 1995 |
Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors.
Topics: Antineoplastic Agents; Etoposide; Female; Half-Life; Humans; Infusions, Intravenous; Linear Models; Male; Metabolic Clearance Rate; Neoplasms; Organophosphorus Compounds | 1996 |
Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Biological Availability; Chromatography, High Pressure Liquid; Etoposide; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Organophosphorus Compounds; Prodrugs | 1996 |
Phase I and pharmacokinetic study of etoposide phosphate.
Topics: Adult; Aged; Antineoplastic Agents; Diarrhea; Dose-Response Relationship, Drug; Etoposide; Humans; Middle Aged; Neoplasms; Organophosphorus Compounds; Regression Analysis; Thrombocytopenia | 1995 |
Phase I study of high-dose etoposide phosphate in man.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Combined Modality Therapy; Etoposide; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Organophosphorus Compounds | 1996 |
A pharmacodynamic evaluation of hematologic toxicity observed with etoposide phosphate in the treatment of cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Etoposide; Female; Granulocytes; Hematologic Diseases; Humans; Leukocyte Count; Male; Middle Aged; Models, Biological; Organophosphorus Compounds; Regression Analysis | 1996 |
A phase I study of etoposide phosphate plus paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Organophosphorus Compounds; Paclitaxel | 1996 |
Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Small Cell; Drug Monitoring; Etoposide; Feasibility Studies; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Organophosphorus Compounds; Prodrugs | 1996 |
Clinical studies with etoposide phosphate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Organophosphorus Compounds; Remission Induction | 1996 |
Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Cross-Over Studies; Etoposide; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Organophosphorus Compounds; Prodrugs; Therapeutic Equivalency | 1996 |
Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Agents; Biological Availability; Etoposide; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Organophosphorus Compounds; Treatment Outcome | 1997 |
Phase I study of high dose etoposide phosphatase with filgrastim (G-CSF) in the treatment of advanced refractory malignancies.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Marrow Diseases; Drug Resistance, Neoplasm; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Male; Middle Aged; Neoplasms; Organophosphorus Compounds; Platelet Count; Recombinant Proteins | 1997 |
Phase I study of etoposide phosphate (etopophos) as a 30-minute infusion on days 1, 3, and 5.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Half-Life; Hemoglobins; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Organophosphorus Compounds; Thrombocytopenia | 1995 |
A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organophosphorus Compounds | 1998 |
Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: a phase II study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Organophosphorus Compounds; Survival Analysis; Treatment Outcome | 2001 |
Bioequivalence investigation of high-dose etoposide and etoposide phosphate in lymphoma patients.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cross-Over Studies; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Humans; Ifosfamide; Infusions, Intravenous; Lymphoma; Middle Aged; Organophosphorus Compounds; Prodrugs; Therapeutic Equivalency | 2001 |
Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chromatography, High Pressure Liquid; Etoposide; Hodgkin Disease; Humans; Life Expectancy; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Multiple Myeloma; Organophosphorus Compounds; Stem Cell Transplantation; Time Factors; Transplantation, Autologous | 2003 |
Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Female; Humans; Middle Aged; Organophosphorus Compounds; Ovarian Neoplasms; Quality of Life; Recurrence; Topotecan | 2005 |
Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organophosphorus Compounds; Paclitaxel; Topotecan | 2005 |
Prognostic value of pretreatment plasma D-dimer level in dogs with intermediate to high-grade non-Hodgkin lymphoma.
Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Double-Blind Method; Etoposide; Female; Fibrin Fibrinogen Degradation Products; Lymphoma, Non-Hodgkin; Male; Organophosphorus Compounds; Podophyllotoxin; Prognosis; Thymidine Kinase | 2021 |
59 other study(ies) available for etoposide phosphate and etoposide
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate.
Topics: Alkaline Phosphatase; Animals; Antibodies, Monoclonal; Biotransformation; Carcinoembryonic Antigen; Cell Line; Colorectal Neoplasms; Etoposide; Mice; Mice, Inbred DBA; Mice, Nude; Organophosphorus Compounds; Prodrugs; Tissue Distribution | 1992 |
Antitumor effects of antibody enzyme conjugates in combination with prodrugs.
Topics: Alkaline Phosphatase; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cattle; Colonic Neoplasms; Combined Modality Therapy; Etoposide; Humans; Immunotoxins; Lung Neoplasms; Mice; Mitomycins; Organophosphorus Compounds; Prodrugs; Tumor Cells, Cultured | 1990 |
Preclinical antitumor activity of a soluble etoposide analog, BMY-40481-30.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Screening Assays, Antitumor; Etoposide; Humans; Leukemia L1210; Leukemia P388; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; Neoplasm Transplantation; Organophosphorus Compounds; Tumor Cells, Cultured | 1990 |
Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates.
Topics: Adenocarcinoma; Alkaline Phosphatase; Animals; Antibodies, Monoclonal; Biotransformation; Etoposide; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mitomycins; Neoplasm Transplantation; Organophosphorus Compounds; Transplantation, Heterologous; Tumor Cells, Cultured | 1989 |
Assessment of toxicokinetics and toxicodynamics following intravenous administration of etoposide phosphate in beagle dogs.
Topics: Animals; Antineoplastic Agents; Dogs; Drug Stability; Edetic Acid; Etoposide; Infusions, Intravenous; Male; Organophosphorus Compounds | 1995 |
Effects of gender, age, and race on the pharmacokinetics of etoposide after intravenous administration of etoposide phosphate in cancer patients.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Area Under Curve; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Data Interpretation, Statistical; Etoposide; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Organophosphorus Compounds; Racial Groups; Sex Factors | 1996 |
A pharmacoeconomic evaluation of cisplatin in combination with either etoposide or etoposide phosphate in small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Costs and Cost Analysis; Economics, Pharmaceutical; Etoposide; Humans; Lung Neoplasms; Models, Economic; Organophosphorus Compounds | 1996 |
Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione.
Topics: Animals; Antineoplastic Agents; Arsenites; ATP-Binding Cassette Transporters; Bone Marrow; Cell Line; Cell Survival; Drug Resistance, Multiple; Etoposide; Female; Glutamate-Cysteine Ligase; Glutathione; Male; Mice; Mice, Knockout; Multidrug Resistance-Associated Proteins; Organ Specificity; Organophosphorus Compounds; Sodium Compounds; Stem Cells | 1997 |
Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile.
Topics: Antineoplastic Agents, Phytogenic; Bile; Biotransformation; Etoposide; Gastric Juice; Humans; In Vitro Techniques; Organophosphorus Compounds; Prodrugs | 1997 |
Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Etoposide; Kidney; Male; Mice; Mice, Inbred Strains; Mice, Knockout; Mouth Mucosa; Organophosphorus Compounds; Oropharynx; Seminiferous Tubules; Stomatitis; Testis; Tongue | 1998 |
Separation of etoposide phosphate and methotrexate by capillary zone electrophoresis using UV detection with a high sensitivity cell.
Topics: Antineoplastic Agents; Electrophoresis, Capillary; Etoposide; Female; Humans; Methotrexate; Organophosphorus Compounds | 1998 |
Severe ocular and orbital toxicity after intracarotid etoposide phosphate and carboplatin therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carotid Artery, Internal; Etoposide; Eye Diseases; Glioblastoma; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Orbital Diseases; Organophosphorus Compounds; Tomography, X-Ray Computed | 1999 |
Successful rechallenge with etoposide phosphate after an acute hypersensitivity reaction to etoposide.
Topics: Adult; Antineoplastic Agents; Drug Hypersensitivity; Etoposide; Female; Humans; Organophosphorus Compounds | 1999 |
Etoposide as a virocidal anticytomegalovirus therapy: intravitreal toxicology and pharmacology in rabbits.
Topics: Animals; Antiviral Agents; Cattle; Cell Count; Cells, Cultured; Cytomegalovirus Infections; Dose-Response Relationship, Drug; Electroretinography; Ethanol; Etoposide; Female; Injections; Organophosphorus Compounds; Pigment Epithelium of Eye; Rabbits; Retina; Solvents; Vitreous Body | 1999 |
Complications of systemic chemotherapy as treatment of retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cyclosporine; Cytarabine; Etoposide; Female; Fever; Humans; Infant; Male; Methotrexate; Neutropenia; Organophosphorus Compounds; Retinal Neoplasms; Retinoblastoma; Thrombocytopenia; Vincristine | 2000 |
Unexpected neurotoxicity of etoposide phosphate administered in combination with other chemotherapeutic agents after blood-brain barrier modification to enhance delivery, using propofol for general anesthesia, in a rat model.
Topics: Anesthesia, General; Anesthetics, Intravenous; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Disease Models, Animal; Etoposide; Female; Neurotoxicity Syndromes; Organophosphate Poisoning; Organophosphorus Compounds; Propofol; Rats; Rats, Long-Evans | 2000 |
High-dose etoposide phosphate and G-CSF mobilizes peripheral blood stem cells in patients that previously failed to mobilize.
Topics: Adult; Choriocarcinoma; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Germinoma; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Infant; Lymphoma, Non-Hodgkin; Male; Middle Aged; Organophosphorus Compounds; Therapeutic Equivalency; Transplantation Conditioning; Whole-Body Irradiation | 2001 |
Simultaneous quantification of etoposide and etoposide phosphate in human plasma by capillary electrophoresis using laser-induced native fluorescence detection.
Topics: Antineoplastic Agents; Electrophoresis, Capillary; Etoposide; Humans; Lasers; Male; Organophosphorus Compounds; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence | 2001 |
Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide.
Topics: Adult; Antineoplastic Agents; Drug Hypersensitivity; Etoposide; Humans; Infusions, Intravenous; Male; Organophosphorus Compounds | 2002 |
Determination of etoposide phosphate intermediates by gradient liquid chromatography using postcolumn derivatization with cuprammonium hydroxide.
Topics: Antineoplastic Agents; Chromatography, Liquid; Etoposide; Hydroxides; Organophosphorus Compounds; Prodrugs; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2002 |
Current status and future of relapsed primary central nervous system lymphoma (PCNSL).
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Organophosphorus Compounds; Radioimmunotherapy; Recurrence; Rituximab; Time Factors | 2003 |
Membrane-bound alkaline phosphatase gene induces antitumor effect by G2/M arrest in etoposide phosphate-treated cancer cells.
Topics: Alkaline Phosphatase; Animals; Cell Membrane; Etoposide; Flow Cytometry; G2 Phase; Mice; Mice, Inbred BALB C; Mitosis; Organophosphorus Compounds; Polymerase Chain Reaction; Rats | 2003 |
Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Cohort Studies; Disease Progression; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Organophosphorus Compounds; Receptors, Estrogen; Time Factors | 2003 |
Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Blotting, Northern; Catalysis; Cell Line, Tumor; Cisplatin; DNA Repair; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Leukemia; Mice; Mice, Inbred DBA; Mutation, Missense; Naphthalenes; Neoplasm Transplantation; Neoplasms, Experimental; Organophosphorus Compounds; Pyrans; RNA, Messenger; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2004 |
Quantification of etoposide and etoposide phosphate in human plasma by micellar electrokinetic chromatography and near-field thermal lens detection.
Topics: Chromatography, Micellar Electrokinetic Capillary; Etoposide; Humans; Lenses; Molecular Structure; Organophosphorus Compounds; Sensitivity and Specificity; Surface Properties; Temperature | 2004 |
Particular cutaneous side effects with etoposide-containing courses: is VP16 or etoposide phosphate responsible?
Topics: Adolescent; Anal Canal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Etoposide; Fingers; Humans; Infant; Infant, Newborn; Neoplasms; Organophosphorus Compounds; Retrospective Studies; Skin Diseases; Toes | 2005 |
Analysis of the in vivo functions of Mrp3.
Topics: Animals; Bile Acids and Salts; Cell Line; Dose-Response Relationship, Drug; Etoposide; Female; Gene Silencing; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Multidrug Resistance-Associated Proteins; Organophosphorus Compounds; Pregnancy | 2005 |
Low dose leflunomide activates PI3K/Akt signalling in erythroleukemia cells and reduces apoptosis induced by anticancer agents.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Proliferation; Cell Survival; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Activation; Etoposide; Humans; Isoxazoles; K562 Cells; Leflunomide; Leukemia, Erythroblastic, Acute; MAP Kinase Kinase 4; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 8; NF-kappa B; Organophosphorus Compounds; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Staurosporine | 2006 |
Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Chlorpheniramine; Drug Hypersensitivity; Etoposide; Female; Humans; Hydrocortisone; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Organophosphorus Compounds | 2008 |
Primary meningeal CNS lymphoma treated with intra-arterial chemotherapy and blood-brain barrier disruption.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Central Nervous System Neoplasms; Enzyme Inhibitors; Etoposide; Female; Humans; Injections, Intra-Arterial; Injections, Intravenous; Lymphoma, Large-Cell, Immunoblastic; Magnetic Resonance Imaging; Methotrexate; Middle Aged; Organophosphorus Compounds | 2008 |
Wipe sampling procedure coupled to LC-MS/MS analysis for the simultaneous determination of 10 cytotoxic drugs on different surfaces.
Topics: Antineoplastic Agents; Camptothecin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Deoxycytidine; Doxorubicin; Epirubicin; Etoposide; Gemcitabine; Ifosfamide; Irinotecan; Methotrexate; Organophosphorus Compounds; Surface Properties; Tandem Mass Spectrometry; Vincristine | 2012 |
Anaphylactic reaction to etoposide phosphate.
Topics: Anaphylaxis; Antineoplastic Agents; Etoposide; Female; Humans; Infant; Leukemia; Organophosphorus Compounds; Skin Neoplasms | 2012 |
Determination of the external contamination and cross-contamination by cytotoxic drugs on the surfaces of vials available on the Swiss market.
Topics: Antineoplastic Agents; Drug Packaging; Environmental Monitoring; Equipment Contamination; Etoposide; Humans; Organophosphorus Compounds | 2014 |
Hypersensitivity reactions to etoposide phosphate.
Topics: Adult; Antineoplastic Agents; Drug Hypersensitivity; Etoposide; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Organophosphorus Compounds; Young Adult | 2014 |
Protein phosphatase 2A promotes hepatocellular carcinogenesis in the diethylnitrosamine mouse model through inhibition of p53.
Topics: Animals; Biopsy; Carcinoma, Hepatocellular; Diethylnitrosamine; Disease Models, Animal; Etoposide; Gene Expression Regulation, Enzymologic; Hepacivirus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Mice; Mice, Inbred C57BL; Mice, Transgenic; Organophosphorus Compounds; Phosphorylation; Protein Phosphatase 2; Tumor Suppressor Protein p53 | 2014 |
Structural elaboration of a natural product: identification of 3,3'-diindolylmethane aminophosphonate and urea derivatives as potent anticancer agents.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Etoposide; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Molecular Structure; Organophosphorus Compounds | 2013 |
T-cell chimerism is valuable in predicting early mortality in steroid-resistant acute graft-versus-host disease after myeloablative allogeneic cell transplantation.
Topics: Acute Disease; Adolescent; Adult; Allografts; Cyclophosphamide; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Organophosphorus Compounds; Prednisolone; T-Lymphocyte Subsets; Transplantation Chimera; Transplantation Conditioning; Whole-Body Irradiation; Young Adult | 2014 |
Successful Treatment with Etoposide Base after an Acute Hypersensitivity Reaction to Etoposide Phosphate.
Topics: Acute Disease; Benzyl Alcohols; Carboplatin; Child, Preschool; Drug Hypersensitivity; Etoposide; Female; Humans; Infusions, Intravenous; Medulloblastoma; Organophosphorus Compounds | 2016 |
Theranostic etoposide phosphate/indium nanoparticles for cancer therapy and imaging.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Drug Carriers; Etoposide; G2 Phase Cell Cycle Checkpoints; Humans; Indium; Lung Neoplasms; M Phase Cell Cycle Checkpoints; Mice; Mice, Nude; Nanoparticles; Organophosphorus Compounds; Theranostic Nanomedicine; Xenograft Model Antitumor Assays | 2015 |
Transdermal Delivery of Etoposide Phosphate II: In Vitro In Vivo Correlations (IVIVC).
Topics: Administration, Cutaneous; Algorithms; Animals; Antineoplastic Agents; Area Under Curve; Chemistry, Pharmaceutical; Drug Delivery Systems; Etoposide; In Vitro Techniques; Iontophoresis; Organophosphorus Compounds; Rabbits; Skin Absorption; Swine | 2016 |
Transdermal Delivery of Etoposide Phosphate I: In Vitro and In Vivo Evaluation.
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents; Area Under Curve; Chromatography, High Pressure Liquid; Drug Delivery Systems; Etoposide; Female; Iontophoresis; Irritants; Microdialysis; Organophosphorus Compounds; Rabbits; Skin; Skin Absorption; Swine | 2016 |
Etoposide phosphate hypersensitivity overcome using a desensitisation programme enabling optimal therapy for relapsed Hodgkin lymphoma.
Topics: Adult; Desensitization, Immunologic; Drug Hypersensitivity; Etoposide; Hodgkin Disease; Humans; Male; Organophosphorus Compounds; Recurrence | 2017 |
Disruption of the association between drug transporter and actin cytoskeleton abolishes drug resistance in hypertrophic scar.
Topics: Actin Cytoskeleton; Adolescent; Adult; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cicatrix, Hypertrophic; Drug Resistance; Etoposide; Female; Fibroblasts; Gene Expression Regulation; Humans; Male; Multidrug Resistance-Associated Proteins; Organophosphorus Compounds; Skin; Verapamil; Young Adult | 2017 |
Preclinical Acute Ocular Safety Study of Combined Intravitreal Carboplatin and Etoposide Phosphate for Retinoblastoma.
Topics: Animals; Antineoplastic Agents; Carboplatin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electroretinography; Etoposide; Intravitreal Injections; Male; Neoplasms, Experimental; Ophthalmoscopy; Organophosphorus Compounds; Rabbits; Retina; Retinal Neoplasms; Retinoblastoma; Treatment Outcome; Visual Acuity | 2017 |
Dose escalation study to evaluate safety, tolerability and efficacy of intravenous etoposide phosphate administration in 27 dogs with multicentric lymphoma.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Dog Diseases; Dogs; Etoposide; Lymphoma; Neoplasm Grading; Neoplasm Staging; Organophosphorus Compounds; Treatment Outcome; Tumor Burden | 2017 |
Unexpected acute renal injury after high-dose etoposide phosphate and total body irradiation in children undergoing hematopoietic stem cell transplantation.
Topics: Acute Kidney Injury; Adolescent; Antineoplastic Agents; Child; Child, Preschool; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Organophosphorus Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Whole-Body Irradiation | 2017 |
Alkaline phosphatase-triggered assembly of etoposide enhances its anticancer effect.
Topics: Alkaline Phosphatase; Animals; Antineoplastic Agents, Phytogenic; Body Weight; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Etoposide; HeLa Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Naphthalenes; Neoplasms, Experimental; Oligopeptides; Organophosphorus Compounds; Particle Size; Structure-Activity Relationship | 2018 |
Acute kidney injury after high dose etoposide phosphate: A retrospective study in children receiving an allogeneic hematopoetic stem cell transplantation.
Topics: Acute Kidney Injury; Antineoplastic Agents; Child; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Organophosphorus Compounds; Prognosis; Retrospective Studies; Survival Rate; Transplantation Conditioning | 2018 |
Should we replace etoposide phosphate by etoposide for allogeneic hematopoetic stem-cell transplantation in children?
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Child; Etoposide; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Organophosphorus Compounds; Prognosis; Transplantation Conditioning; Transplantation, Homologous | 2018 |
Stability of vincristine sulfate, doxorubicin hydrochloride and etoposide phosphate admixtures in polyisoprene elastomeric pump supporting transition of the EPOCH regimen to outpatient care.
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Stability; Elastomers; Etoposide; Humans; Infusion Pumps; Organophosphorus Compounds; Vincristine | 2019 |
Etoposide phosphate for pediatric orthopedic malignancies after intravenous etoposide hypersensitivity.
Topics: Adolescent; Bone Neoplasms; Drug Hypersensitivity; Etoposide; Humans; Male; Organophosphorus Compounds; Osteosarcoma; Sarcoma, Ewing | 2020 |
Physical and chemical stability of a generic etoposide formulation as an alternative to etoposide phosphate.
Topics: Antineoplastic Agents; Chemical Precipitation; Chromatography, Liquid; Drug Packaging; Drug Stability; Drug Storage; Drugs, Generic; Etoposide; Half-Life; Hydrolysis; Mass Spectrometry; Organophosphorus Compounds; Solvents; Temperature | 2020 |
Partial response to carboplatin, etoposide phosphate, and atezolizumab in a pediatric patient with high-grade metastatic tumor with rhabdoid and focal neuroendocrine features.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Etoposide; Humans; Liver Neoplasms; Male; Neoplasm Grading; Neuroendocrine Tumors; Organophosphorus Compounds; Rhabdoid Tumor; Treatment Outcome | 2020 |
Epithelioid Hyalinizing Sarcoma With MGA-NUTM1 Fusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Transcription Factors; Cyclophosphamide; Dactinomycin; Etoposide; Foot; Foot Bones; Gene Fusion; Humans; Hyalin; Ifosfamide; Magnetic Resonance Imaging; Male; Middle Aged; Muscle, Skeletal; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Nuclear Proteins; Organophosphorus Compounds; Sarcoma; Vincristine | 2020 |
Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Etoposide; Humans; Male; Organophosphorus Compounds; Prostatic Neoplasms, Castration-Resistant; Topoisomerase II Inhibitors | 2020 |
Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Organophosphorus Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2021 |
Dramatic Recovery after Etoposide Phosphate Infusion for Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome following Treatment with Tisagenlecleucel in a Young Patient with Relapsed Acute Lymphoblastic Leukemia: A Case Report.
Topics: Acute Disease; Etoposide; Humans; Lymphohistiocytosis, Hemophagocytic; Macrophage Activation Syndrome; Organophosphorus Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Antigen, T-Cell | 2022 |
Acute kidney injury in patients receiving high-dose etoposide phosphate as conditioning prior to hematopoietic stem cell transplantation in hematologic malignancies may be associated with elevated body mass index.
Topics: Acute Kidney Injury; Body Mass Index; Etoposide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning | 2023 |